NovaBridge (NBP) Director Robert A. Lenz Receives RSUs; Shares Withheld

What Happened

• Robert A. Lenz, a director of NovaBridge Biosciences (NBP), had restricted stock units (RSUs) vest on August 22, 2026. The vesting resulted in the acquisition of 17,218 ordinary shares (reported as 7,486 ADSs). Simultaneously, 7,486 ADSs were disposed of at $0.00 — consistent with shares being withheld to cover tax withholding obligations rather than a market sale. No cash purchase or open-market sale was reported.

Key Details

• Transaction date: August 22, 2026
• Acquired: 17,218 ordinary shares (reported as 7,486 ADSs) — recorded as a derivative conversion/vesting (transaction code M)
• Disposed: 7,486 ADSs at $0.00 (likely tax withholding)
• Price/Value: Acquisition shows N/A (RSU vesting); disposal recorded at $0.00 (withholding), no cash proceeds reported
• Shares owned after transaction: Not specified on the Form 4 excerpt provided
• Footnotes of note:
  • F1: Ordinary shares may be represented by ADSs; 10 ADSs = 23 ordinary shares (explains the 7,486 ADS / 17,218 share relationship)
  • F2–F4: The reported securities are ADSs; each RSU equals one ADS
  • F5: These RSUs were granted Aug 22, 2025 (22,460 RSUs) and vest in three equal annual installments on Aug 22, 2026–2028 (this is the first tranche)
• Filing: Form filed Aug 25, 2026 for the Aug 22, 2026 transaction (no late-filing flag noted in the provided data)

Context

• This filing reflects RSU vesting and routine tax-withholding, not an open-market sale or a purchase — a common administrative step when equity awards vest. Such withholdings do not necessarily signal insider sentiment about the company's stock; purchases would generally be a stronger positive signal.